RITUXAN MAINTENANCE THERAPY

• FLASCO
• June 28, 2016
• Clinical Practice Updates, Drugs

NATIONAL COMPREHENSIVE CANCER NETWORK®(NCCN®) STATUS1

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®) CATEGORY DESIGNATION1
Rituximab (RITUXAN®) is included in the NCCN Guidelines® with a category 1 designation for first-line maintenance therapy (one 375 mg/m2 dose every 2 months for 2 years) in follicular lymphoma patients initially presenting with high tumor burden1
Note: Category 1 designation is given based upon high-level evidence and uniform NCCN consensus that the intervention is appropriate.1

For full definitions of the NCCN Categories of Evidence and Consensus, please refer to the NCCN Guidelines, available online at www.nccn.org.